CalciMedica Secures Loan Extension to 2029, Adds $3M Equity Conversion and New Warrants
CALC sits 74% above its 52-week low of $0.461 on light trading volume (0.3× avg).
Summary
CalciMedica extended its $10 million loan with Avenue, pushing maturity to September 2029 and interest-only payments to September 2027. This critical financing provides much-needed runway, especially given the company's prior disclosure of substantial doubt about its going concern. However, the terms include a new feature allowing conversion of up to $3 million of principal into equity at $1.00 per share, plus the issuance of a new 1,000,000-share warrant at $1.00 and a reduction in an existing warrant's exercise price to $1.00. While the $1.00 conversion/warrant price is above the current stock price of $0.80, these provisions introduce significant potential future dilution for existing shareholders.
At the time of this announcement, CALC was trading at $0.80 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $12.7M. The 52-week trading range was $0.46 to $7.20. This news item was assessed with neutral market sentiment and an importance score of 8 out of 10. Source: Wiseek News.